China · Delayed Price · Currency is CNY Hybio Pharmaceutical Company Description
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally.
The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; and platform for CDMO services, which includes peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory and dossier support, etc. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.
| Country | China |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,035 |
| CEO | Yu Pinxiang |
Contact Details
Address: Hanyu Innovation Industry Building Wuhan China | |
| Phone | 86 755 2658 6015 |
Stock Details
| Ticker Symbol | 300199 |
| Exchange | Shenzhen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000011T7 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shaogui Zeng | President and Chairman |
| Yu Pinxiang | Executive President and Director |
| Honghong Tu | Vice President and Chief Financial Officer |
| Min Zhang | Vice President of Human Resources, Corporate Management and Administrative Department |
| Baole Zhang | Vice President |
| Caiyun Bian | Accounting Supervisor |
| Yu Liu | Vice President of Marketing |